Video Reports

Embed this video

Copy Code

Link to this video

Get LinkEmbedLicenseRecommend (-)Print
Bookmark and Share

By Erik Kobayashi-Solomon | 06-30-2009 12:26 PM

Upside Attraction to J&J

Morningstar's Damien Conover discusses the prospects for J&J's stent and drug pipelines.

Erik Kobayashi-Solomon: Hi, I'm Erik Kobayashi-Solomon. I'm co-editor of Morningstar's OptionInvestor.

Today, it's my great pleasure to welcome Damien Conover, who's the editor of Morningstar's Healthcare Observer. This is a specialized newsletter covering very detailed topics in the health-care industry. Damien, thanks for coming today.

Damien Conover: Great, thanks for having me, Erik.

Kobayashi-Solomon: Right at the end of February, I recommended an investment to our readers, where they would basically buy the upside to J&J, one of your companies; all the upside from $60 on, and bought it for $3--sounds like a really good deal to me, and it's been working out well.

So, I just wanted to ask you a little bit more about J&J as an investment idea. Mainly what I want to ask you about are their longer-term projects, especially their stent pipeline, and also the drug pipeline. How's that looking to you, those two divisions?

Conover: Both of those divisions are very important. Let's take them one at a time.

Read Full Transcript
{0}-{1} of {2} Comments
{0}-{1} of {2} Comment
  • This post has been reported.
  • Comment removed for violation of Terms of Use ({0})
    Please create a username to comment on this article